Eagle Pharmaceuticals files for a $50 million IPO


Shutterstock photo

Eagle Pharmaceuticals, which develops and sells enhanced injectable products, filed on Friday with the SEC to raise up to $50 million in an initial public offering. The Woodcliff Lake, NJ-based company, which was founded in 2007 and booked $14 million in sales for the fiscal year ended September 30, 2013, plans to list on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals initially filed confidentially on October 21, 2013. Piper Jaffray and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com